Fulvestrant 500mg Versus Exemestane in Postmenopausal Metastatic Breast Cancer (MBC) Resistant to Adjuvant Non-Steroidal Aromatase Inhibitors (NSAI) in Clinical Practice – A Multicenter Retrospective Study
Clinical Breast Cancer - United States
doi 10.1016/j.clbc.2019.01.015
Full Text
Open PDFAbstract
Available in full text
Date
June 1, 2019
Authors
Publisher
Elsevier BV